



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	April 27, 2020

CORLANOR[®] (ivabradine)

LENGTH OF AUTHORIZATION: ONE YEAR

CLINICAL NOTES:

Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction $\leq 35\%$, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

REVIEW CRITERIA:

Adults:

- Patient must have a diagnosis of stable, symptomatic chronic heart failure (e.g. NYHA Class II, III, or IV heart failure); **AND**
- Documentation of left ventricular ejection fraction less than or equal to 35%; **AND**
- Patient must be in sinus rhythm with a resting heart rate greater than or equal to 70 beats per minute; **AND**
- Documentation of blood pressure greater than or equal to 90/50 mmHg; **AND**
- Documentation of previous treatment, intolerance, or contraindication to maximally tolerated doses of at least one beta-blocker (e.g., carvedilol, metoprolol, or bisoprolol).

Pediatric Patients (6 months to less than 18 years of age):

- Patient is 6 months of age or older; **AND**
- Patient has the diagnosis of stable symptomatic heart failure due to dilated cardiomyopathy; **AND**
- Patient is in sinus rhythm with an elevated heart rate.

CONTINUATION OF THERAPY:

- Patient must continue to meet the above initial criteria; **AND**
- Patient must continue to tolerate therapy; **AND**
- Patient must continue to respond to therapy (e.g. resting heart rate between 50-60 beats per minute).



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	April 27, 2020

DOSING AND ADMINISTRATION:

Adults:

Recommended starting dose is 5 mg by mouth twice daily with food for two weeks, then adjust the dose to achieve a resting heart rate between 50-60 beats per minute; Maximum is 7.5 mg twice daily (15mg daily).

Info: for pts with LVEF 35% or lower and resting HR at least 70; start 2.5 mg by mouth twice daily in patients with conduction defect history or hemodynamic compromise risk; give with meals.

Pediatric patients 6 months and older (<40kg)

Recommended starting dose is 0.05mg/kg twice daily with food Assess patient at two-week intervals and adjust dose by 0.05 mg/kg to target a heart rate (HR) reduction of at least 20%, based on tolerability. The maximum dose is 0.2 mg/kg twice daily for patients 6 months to less than 1 year old, and 0.3 mg/kg twice daily for patients 1 year old and older, up to a total of 7.5 mg twice daily.

Pediatric Patients 6 months and older (>40kg)

Recommended starting dose of Corlanor tablets in pediatric patients weighing more than 40 kg is 2.5 mg twice daily with food. Assess patient at two-week intervals and adjust dose by 2.5 mg to target a heart rate (HR) reduction of at least 20%, based on tolerability. The maximum dose is 7.5 mg twice daily.